---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-059435"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2025-06-13T23:59:59+00:00"
generated_at: "2026-05-19T09:14:15.968079+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma shareholders elect director, ratify auditor at 2025 annual meeting

## Summary
- Quorum of 14,605,167 shares (61.86%) present out of 23,606,443 outstanding shares.
- Class III director James Oliviero elected with 9,882,555 votes for, 240,327 against, 782 abstentions.
- Ratification of Kesselman & Kesselman as independent auditor approved with 14,561,983 votes for, 40,324 against.
- All proposals passed as detailed in the April 28, 2025 proxy statement.

## SEC filing metadata
- accession: 0001104659-25-059435
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2025-06-13T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465925059435/0001104659-25-059435-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465925059435/tm2518009d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-059435
- JSON: https://secwatch.observer/filing/0001104659-25-059435.json
- Plain text: https://secwatch.observer/filing/0001104659-25-059435.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.